289 related articles for article (PubMed ID: 11885830)
1. Selling drugs to doctors--it's marketing, not education.
Cooper R; Hoffman J
Br J Gen Pract; 2002 Feb; 52(475):168-9. PubMed ID: 11885830
[No Abstract] [Full Text] [Related]
2. Selling drugs to the public--should the UK follow the example of the US?
Frey J
Br J Gen Pract; 2002 Feb; 52(475):170-1. PubMed ID: 11885831
[No Abstract] [Full Text] [Related]
3. [Rules of the game in drug marketing].
Palva E
Duodecim; 1999; 115(20):2187, 2189. PubMed ID: 11973920
[No Abstract] [Full Text] [Related]
4. The role of direct-to-consumer advertising.
Navarro RP
Manag Care Interface; 1998 Nov; 11(11):79-80, 82. PubMed ID: 10187419
[No Abstract] [Full Text] [Related]
5. Pharmaceuticals and medical devices: FDA oversight.
Berry MD
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
[No Abstract] [Full Text] [Related]
6. Marketing drugs: debating the real cost. Concern about close ties between doctors and pharmaceutical firms are prompting new financial disclosure laws and education efforts.
Brand R
State Legis; 2008 Sep; 34(8):26-9. PubMed ID: 18754159
[No Abstract] [Full Text] [Related]
7. Direct-to-consumer genetic tests, government oversight, and the First Amendment: what the government can (and can't) do to protect the public's health.
Javitt GH; Stanley E; Hudson K
Oklahoma Law Rev; 2004; 57(2):251-302. PubMed ID: 15658034
[No Abstract] [Full Text] [Related]
8. An insider's perspective: defense of the pharmaceutical industry's marketing practices.
Johar K
Albany Law Rev; 2012-2013; 76(1):299-334. PubMed ID: 23577377
[No Abstract] [Full Text] [Related]
9. Major issues in marketing regulation.
Pines WL
Food Drug Law J; 1997; 52(3):297-302. PubMed ID: 10343028
[No Abstract] [Full Text] [Related]
10. Marketing pharmaceuticals: a constitutional right to sell prescriber-identified data?
Gostin LO
JAMA; 2012 Feb; 307(8):787-8. PubMed ID: 22357827
[No Abstract] [Full Text] [Related]
11. Pharmaceuticals and medical devices: business practices. Issue brief.
Thomson Reuters/West
Issue Brief Health Policy Track Serv; 2011 Jan; ():1-44. PubMed ID: 21374840
[No Abstract] [Full Text] [Related]
12. Claim substantiation in the health care industry.
Fergenson PE
Hosp Mater Manage Q; 1992 May; 13(4):20-6. PubMed ID: 10117377
[No Abstract] [Full Text] [Related]
13. Big bad pharma: an ethical analysis of physician-directed and consumer-directed marketing tactics.
Connors AL
Albany Law Rev; 2009 Sep; 73(1):243-82. PubMed ID: 20235401
[No Abstract] [Full Text] [Related]
14. Voluntary self-regulatory codes: what should we expect?
Lexchin J
Am J Bioeth; 2003; 3(3):49-50. PubMed ID: 14594491
[No Abstract] [Full Text] [Related]
15. Paternalistic or protective? Freedom of expression and direct-to-consumer drug advertising policy in Canada.
Gold JL
Health Law Rev; 2003; 11(2):30-6. PubMed ID: 15706698
[No Abstract] [Full Text] [Related]
16. Legislative and non-legislative regulations concerning Rx drug advertisement in the European Union and the United States--comparative analysis.
Czerw A; Religioni U
Acta Pol Pharm; 2012; 69(4):779-87. PubMed ID: 22876622
[TBL] [Abstract][Full Text] [Related]
17. Understanding government regulation of the marketing and advertising of medical devices, drugs, and biologics: the challenges of the Internet.
Reichertz PS
Food Drug Law J; 1997; 52(3):303-8. PubMed ID: 10343029
[No Abstract] [Full Text] [Related]
18. Experimenting with direct-to-consumer advertising.
Lancet; 2000 Aug; 356(9230):607. PubMed ID: 10968426
[No Abstract] [Full Text] [Related]
19. Pharmaceuticals and medical devices: business practices. End-of-year issue brief.
Jones TM
Issue Brief Health Policy Track Serv; 2010 Jan; ():1-58. PubMed ID: 20213918
[No Abstract] [Full Text] [Related]
20. Pharmaceutical industry restructuring and new marketing approaches: enforcement responses.
Mahinka SP; Sanzo KM
Food Drug Law J; 1995; 50(2):313-25. PubMed ID: 10343000
[No Abstract] [Full Text] [Related]
[Next] [New Search]
